With the debut of remarkably effective weight-loss drugs, America's high obesity rate and its uniquely astronomical prescription drug pricing appear to be set on a catastrophic collision course—one that threatens to "bankrupt our entire health care system," according to a new Senate report that modeled the economic impact of the drugs in different uptake scenarios.
The HELP committee analysis cited a March Congressional Budget Office (CBO) report that found: "at their current prices, [anti-obesity medicines] would cost the federal government more than it would save from reducing other health care spending—which would lead to an overall increase in the deficit over the next 10 years." Moreover, in April, the head of the CBO said that the drugmakers would have to slash prices of their weight-loss drugs by 90 percent to "get in the ballpark" of not increasing the national deficit.
The HELP committee report offered a relatively simple solution to the problem: Drugmakers should set their US prices to match the relatively low prices they've set in other countries. The report focused on Wegovy because it currently accounts for the most US prescriptions in the new class of weight-loss drugs (GLP-1 drugs). Wegovy is made by Denmark-based Novo Nordisk.
In the US, the estimated net price (after rebates) of Wegovy is $809 per month. In Denmark, the price is $186 per month. A study by researchers at Yale estimated that drugs like Wegovy can be profitably manufactured for less than $5 per month.
If Novo Nordisk set its US prices for Wegovy to match the Danish price, spending to treat half of US adults with obesity would drop from $411 billion to $94.5 billion, a roughly $316.5 billion savings.
Read the article. This is not a US product.
I agree with you though.
True, but its about their operations in the US, which are required to follow US laws. They still need a patent and copyright from the US government for their US operations.
This means their patent for the drug in the US system means they can prevent it from being available to US consumers as a generic.
Also, the issue of the cost is related to how our government isn't allowed to negotiate drug costs like others are.
The drug is made by a foreign company that has a presence in the US. They have a US headquarters for their US business.
Local laws have more to do with the issues raised in the article than the origin country of the company making the drug.
That's like saying T-Mobile is bound by German laws despite operating in the US because it is owned by Deutsche Telecom.